Therapeutic effects of sodium–glucose cotransporter 2 inhibitors in patients with heart failure with preserved ejection fraction: From outcome improvement to potentially favourable influences on atrial fibrillation burden, atrial fibrillation progression and atrial cardiomyopathy

医学 心力衰竭 心房颤动 射血分数 内科学 心脏病学
作者
Giuseppe Boriani,Davide Mei,Jacopo Francesco Imberti
出处
期刊:European Journal of Heart Failure [Wiley]
卷期号:25 (7): 978-980 被引量:2
标识
DOI:10.1002/ejhf.2891
摘要

European Journal of Heart FailureEarly View Invited Editorial Therapeutic effects of sodium–glucose cotransporter 2 inhibitors in patients with heart failure with preserved ejection fraction: from outcome improvement to potentially favourable influences on atrial fibrillation burden, atrial fibrillation progression and atrial cardiomyopathy Giuseppe Boriani, Corresponding Author Giuseppe Boriani [email protected] Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy Corresponding author. Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Via del Pozzo 71, 41124 Modena, Italy. Email: [email protected]Search for more papers by this authorDavide A. Mei, Davide A. Mei Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, ItalySearch for more papers by this authorJacopo F. Imberti, Jacopo F. Imberti Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, ItalySearch for more papers by this author Giuseppe Boriani, Corresponding Author Giuseppe Boriani [email protected] Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy Corresponding author. Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Via del Pozzo 71, 41124 Modena, Italy. Email: [email protected]Search for more papers by this authorDavide A. Mei, Davide A. Mei Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, ItalySearch for more papers by this authorJacopo F. Imberti, Jacopo F. Imberti Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, ItalySearch for more papers by this author First published: 16 May 2023 https://doi.org/10.1002/ejhf.2891 The opinions expressed in this article are not necessarily those of the Editors of the European Journal of Heart Failure or of the European Society of Cardiology. doi: 10.1002/ejhf.2861. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. References 1Sartipy U, Dahlström U, Fu M, Lund LH. Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. JACC Heart Fail 2017; 5: 565– 574. https://doi.org/10.1016/j.jchf.2017.05.001 2Packer M, Lam CSP, Lund LH, Redfield MM. Interdependence of atrial fibrillation and heart failure with a preserved ejection fraction reflects a common underlying atrial and ventricular myopathy. Circulation 2020; 141: 4– 6. https://doi.org/10.1161/CIRCULATIONAHA.119.042996 3DeSa T, Gong T. SGLT2 inhibitors: A new pillar of the heart failure regimen. Rev Cardiovasc Med 2021; 22: 1253– 1269. https://doi.org/10.31083/j.rcm2204133 4Fauchier L, Boriani G, de Groot JR, Kreutz R, Rossing P, Camm AJ. Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus. Europace 2021; 23: 1873– 1891. https://doi.org/10.1093/europace/euab184 5Filippatos G, Farmakis D, Butler J, Zannad F, Ferreira JP, Ofstad AP, et al. EMPEROR-Preserved Trial Committees and Investigators. Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation. Eur J Heart Fail . https://doi.org/10.1002/ejhf.2861 Published online ahead of print 16/04/23. 6Boriani G, Vitolo M, Lane DA, Potpara TS, Lip GY. Beyond the 2020 guidelines on atrial fibrillation of the European Society of Cardiology. Eur J Intern Med 2021; 86: 1– 11. https://doi.org/10.1016/j.ejim.2021.01.006 7Meyer M, Lustgarten D. Beta-blockers in atrial fibrillation – trying to make sense of unsettling results. Europace 2023; 25: 260– 262. https://doi.org/10.1093/europace/euad010 8Tsai WH, Chuang SM, Liu SC, Lee CC, Chien MN, Leung CH, et al. Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: A systematic review and meta-analysis. Sci Rep 2021; 11:15364. https://doi.org/10.1038/s41598-021-94945-4 9Boriani G, Vitolo M, Diemberger I, Proietti M, Valenti AC, Malavasi VL, et al. Optimizing indices of atrial fibrillation susceptibility and burden to evaluate atrial fibrillation severity, risk and outcomes. Cardiovasc Res 2021; 117: 1– 21. https://doi.org/10.1093/cvr/cvab147 10Malavasi VL, Fantecchi E, Tordoni V, Melara L, Barbieri A, Vitolo M, et al. Atrial fibrillation pattern and factors affecting the progression to permanent atrial fibrillation. Intern Emerg Med 2021; 16: 1131– 1140. https://doi.org/10.1007/s11739-020-02551-5 11Pallisgaard J, Greve AM, Lock-Hansen M, Thune JJ, Fosboel EL, Devereux RB, et al. Atrial fibrillation onset before heart failure or vice versa: What is worst? A nationwide register study. Europace 2023; 25: 283– 290. https://doi.org/10.1093/europace/euac186 12Ong HT, Teo YH, Teo YN, Syn NL, Wee CF, Leong S, et al. Effects of sodium/glucose cotransporter inhibitors on atrial fibrillation and stroke: A meta-analysis. J Stroke Cerebrovasc Dis 2022; 31:106159. https://doi.org/10.1016/j.jstrokecerebrovasdis.2021.106159 13Aziri B, Begic E, Jankovic S, Mladenovic Z, Stanetic B, Kovacevic-Preradovic T, et al. Systematic review of sodium-glucose cotransporter 2 inhibitors: A hopeful prospect in tackling heart failure-related events. ESC Heart Fail 2023; 10(3): 1499– 1530. https://doi.org/10.1002/ehf2.14355 Published online ahead of print 26/03/23. 14Boriani G, Imberti JF, Vitolo M. The burden of atrial fibrillation in patients with preserved or mildly reduced heart failure: A call to action for detecting atrial fibrillation and improving outcome. Eur J Heart Fail 2023; 25: 74– 76. https://doi.org/10.1002/ejhf.2755 15Karamichalakis N, Kolovos V, Paraskevaidis I, Tsougos E. A new hope: Sodium-glucose cotransporter-2 inhibition to prevent atrial fibrillation. J Cardiovasc Dev Dis 2022; 9:236. https://doi.org/10.3390/jcdd9080236 16Donniacuo M, De Angelis A, Telesca M, Bellocchio G, Riemma MA, Paolisso P, et al. Atrial fibrillation: Epigenetic aspects and role of sodium-glucose cotransporter 2 inhibitors. Pharmacol Res 2023; 188:106591. https://doi.org/10.1016/j.phrs.2022.106591 17Boriani G, Vitolo M, Imberti JF. Atrial cardiomyopathy: A derangement in atrial volumes, geometry, function, and pathology with important clinical implications. J Cardiovasc Med (Hagerstown) 2022; 23: 359– 362. https://doi.org/10.2459/JCM.0000000000001316 18Marra AM, Bencivenga L, D'Assante R, Rengo G, Cittadini A. Heart failure with preserved ejection fraction: Squaring the circle between comorbidities and cardiovascular abnormalities. Eur J Intern Med 2022; 99: 1– 6. https://doi.org/10.1016/j.ejim.2022.01.019 Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
科研通AI2S应助刘隅采纳,获得10
4秒前
研友_LN32Mn发布了新的文献求助10
8秒前
缺粥完成签到 ,获得积分10
11秒前
莫冰雪完成签到 ,获得积分10
14秒前
EVEN完成签到 ,获得积分10
21秒前
zwzxtx完成签到 ,获得积分10
25秒前
Huang完成签到 ,获得积分0
26秒前
ryan1300完成签到 ,获得积分10
28秒前
Amikacin完成签到,获得积分10
33秒前
烟熏妆的猫完成签到 ,获得积分10
34秒前
Diligency完成签到 ,获得积分10
38秒前
笨笨青筠完成签到 ,获得积分10
41秒前
无为完成签到 ,获得积分10
45秒前
失眠的安卉完成签到,获得积分10
45秒前
小彭友完成签到 ,获得积分10
52秒前
江流有声完成签到 ,获得积分10
58秒前
xiao完成签到 ,获得积分10
1分钟前
su完成签到 ,获得积分10
1分钟前
logolush完成签到 ,获得积分10
1分钟前
zhang完成签到 ,获得积分10
1分钟前
zhdjj完成签到 ,获得积分10
1分钟前
sydhwo完成签到 ,获得积分10
1分钟前
无极2023完成签到 ,获得积分10
1分钟前
特别圆的正方形完成签到 ,获得积分10
1分钟前
iShine完成签到 ,获得积分10
1分钟前
会发芽完成签到 ,获得积分10
1分钟前
CC2333完成签到 ,获得积分10
1分钟前
卓矢完成签到 ,获得积分10
1分钟前
jue完成签到 ,获得积分10
1分钟前
GuangboXia完成签到,获得积分10
1分钟前
研友_LN32Mn完成签到,获得积分10
1分钟前
yinhe完成签到 ,获得积分10
1分钟前
Singularity应助科研通管家采纳,获得10
1分钟前
天天快乐应助科研通管家采纳,获得10
1分钟前
Singularity应助科研通管家采纳,获得10
1分钟前
传奇3应助科研通管家采纳,获得10
1分钟前
范白容完成签到 ,获得积分10
1分钟前
但大图完成签到 ,获得积分10
2分钟前
启程牛牛完成签到,获得积分0
2分钟前
高分求助中
좌파는 어떻게 좌파가 됐나:한국 급진노동운동의 형성과 궤적 2500
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Cognitive linguistics critical concepts in linguistics 800
Threaded Harmony: A Sustainable Approach to Fashion 799
Livre et militantisme : La Cité éditeur 1958-1967 500
氟盐冷却高温堆非能动余热排出性能及安全分析研究 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3052652
求助须知:如何正确求助?哪些是违规求助? 2709874
关于积分的说明 7418267
捐赠科研通 2354446
什么是DOI,文献DOI怎么找? 1246020
科研通“疑难数据库(出版商)”最低求助积分说明 605951
版权声明 595921